Moolec Science Announces Successful Closing of Business Combination, Expanding Across Life Sciences and Food-Tech
GRAND CAYMAN, CAYMAN ISLANDS / / June 17, 2025 / Moolec Science SA (NASDAQ:MLEC) ("The Company"; "Moolec"), a science-based food ingredient company focused on producing animal proteins and nutritional oils in plants, today announced the successful closing of its previously announced strategic business combination (the "Business Combination") with Bioceres Group Limited ("Bioceres Group"), Gentle Technologies Corp ("Gentle Tech"), and Nutrecon LLC ("Nutrecon"). With the closing, Moolec emerges as the parent company of a significantly expanded and enhanced enterprise at the forefront of sustainable life sciences and food-tech innovation.
This transformative transaction brings together complementary capabilities across food ingredients, ag-biologicals, precision fermentation, biomaterials, and R&D services, consolidating Moolec's position as a differentiated life science platform focused on sustainable solutions from molecule to ingredient.
The Business Combination, initially announced on April 17, 2025, was ratified by Moolec shareholders at the Extraordinary General Meeting ("EGM") held on June 16, with ~77% of the outstanding shares present at the meeting, and ~98% of the votes cast were in favor of the transaction.
Under the terms of the transaction, Bioceres Group shareholders have exchanged their equity ownership for approximately 6.9 million shares of Moolec. The shareholders of 100% of Nutrecon and 50% of Gentle Tech have received, in exchange for their ownership in these entities, approximately 0.65 million shares of Moolec and 0.5 million Moolec private warrants, each with a strike price of $20.00.
The combined company will continue operating under the name Moolec Science, with its securities trading on NASDAQ under the ticker symbols "MLEC" and "MLECW".
The Board of Directors has appointed Mr. Alejandro Antalich as Chief Executive Officer of Moolec Science. Mr. Antalich brings over 20 years of international leadership experience in biotechnology and life sciences, with a proven track record of scaling sustainable technologies, driving strategic partnerships, M&A, and delivering significant growth through value-creating transactions. Prior to this appointment, he served as CEO of Nutrecon, where he positioned the company as a key innovator in precision fermentation and alternative protein ingredients, and established a state-of-the-art synthetic biology platform providing integrated R&D, contract development, and manufacturing services. Earlier in his career, he led an innovative life sciences company, guiding its international expansion and executing its strategic sale to a global publicly traded corporation in a landmark transaction valued at nearly $300 million.
Key highlights:
Ingredient Innovation: Moolec will continue advancing its flagship molecular farming products, such as Piggy Sooy™ and GLASO™, while integrating Mycofood™ - acquired through Nutrecon - under the Eternal® brand to expand its alternative protein offering.
Biological Ag Expansion: Through Bioceres Group, Moolec will now offer upstream technologies for regenerative agriculture, including biological inputs and climate-smart seeds under the Rizobacter®, ProFarm®, and HB4® brands.
Integrated R&D and Technical Capabilities: With cutting-edge infrastructure through Agrality® and Synbio Powerlabs® - platforms belonging to Bioceres Group and Nutrecon, respectively - Moolec now benefits from in-house R&D, CDMO and regulatory capabilities designed to accelerate the development, testing, and regulatory progression of its technology pipeline.
Emerging Tech & Equipment: The Company will also expand its presence in emerging technologies for grain and biomass transformation, particularly within the biomaterials space, as well as new concepts in farm equipment that integrate material science, electric mobility, and autonomy. These initiatives are currently being developed through subsidiaries of Gentle Tech and Bioceres Group.
Forward Looking Statements
This press release contains "forward-looking statements." Forward-looking statements may be identified by the use of words such as "forecast," "intend," "seek," "target," "anticipate," "believe," "expect," "estimate," "plan," "outlook," and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements with respect to performance, prospects, revenues, and other aspects of the business of Moolec are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors, about which we cannot be certain. We cannot assure you that the forward-looking statements in this press release will prove accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, changes in applicable laws or regulations, the possibility that Moolec may be adversely affected by economic, business and/or other competitive factors, costs related to the scaling up of Moolec's business and other risks and uncertainties, including those included under the header "Risk Factors" in Moolec's Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission ("SEC"), as well as Moolec's other filings with the SEC. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, you should not put undue reliance on these statements.
Contact Information
Press & Media comms@moolecscience.com
Investor Relations ir@moolecscience.com
SOURCE: Moolec Science SA
View the original press release on ACCESS Newswire
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
4 hours ago
- Associated Press
Pizza Vending Machine Business Model: Start Earning Passive Income in 2025
06/18/2025, New York City, New York // KISS PR Brand Story PressWire // Introduction What if you could earn money 24/7 — even while you sleep — with minimal labor, low overhead, and explosive demand? In 2025, thousands of entrepreneurs and property owners across Europe and the United States are doing exactly that through the pizza vending machine business. As food tech advances and consumer preferences shift toward contactless, on-demand service, the vending industry is evolving fast. At the center of this revolution is one hot, cheesy solution: automated pizza vending machines. In this article, we'll break down how the business model works, what you need to start, and how to maximize profits. Whether you're an aspiring investor or a seasoned operator, this guide will show you why pizza vending machine business opportunities are booming — and how you can get in on the action. And when you're ready to launch, trust Vending Expert at to help you build and scale your venture. Why Pizza Vending Is the Future of Fast Food Pizza Is a Universal Favorite No matter the city or continent, pizza is a beloved staple. It's universally recognized, easy to sell, and offers incredible margins. Unlike niche vending options, pizza appeals to all ages and cultures — making it the perfect product for passive vending income. Automation Eliminates Staffing Staffing a restaurant is expensive and complicated. With a pizza vending machine, you: The pizza vending machine business lets you focus on revenue, not recruitment. Flexible Locations, Unlimited Reach You don't need to buy or rent expensive restaurant space. With vending, your business is mobile and scalable. You can place units in: Where there's foot traffic, there's opportunity. How the Pizza Vending Machine Business Works Step 1: Purchase or Lease Your Machine You begin by acquiring a high-performance machine through a trusted distributor like Vending Expert at Machines range in price and size but offer full automation, touchscreen ordering, real-time inventory tracking, and contactless payments. Step 2: Find the Right Location This is critical. Your success hinges on visibility, accessibility, and foot traffic. You can negotiate location partnerships with property managers, campuses, or commercial buildings for a small monthly fee or profit share. Step 3: Stock Ingredients & Maintain The machine holds: Thanks to refrigeration and sanitation systems, these ingredients stay fresh for several days. Most operators restock just 2–3 times a week. Step 4: Go Live & Monitor Remotely Once installed and stocked, your machine is ready to generate income. You'll monitor: All remotely through your mobile dashboard. How Profitable Is the Pizza Vending Machine Business? Let's break down the numbers. Net Profit Estimates Typical gross profit margins range from 45% to 60%, depending on: A well-placed machine can net $3,000–$6,000/month in passive profit. Are Vending Machines Profitable in 2025? (FAQ) Absolutely. The vending industry is thriving — especially in the food automation sector. Here's why: And with people prioritizing convenience, contactless experiences, and speed, pizza vending machine business owners are perfectly positioned for explosive growth in 2025. Key Benefits of the Pizza Vending Machine Business Passive Income Once operational, your machine works for you, not the other way around. Your time investment is minimal — check inventory, restock as needed, monitor sales. That's it. Scalable Model Start with one machine. Grow to ten. Then fifty. The model scales easily across cities and even countries, especially with centralized logistics. Low Barrier to Entry Unlike restaurants or franchises, you don't need: With as little as $30K–$50K, you can own your first machine and begin earning immediately. Strong Consumer Trust Customers today are familiar with self-serve ordering. From airport kiosks to self-checkouts, automation feels natural — not foreign. What Does a Pizza Vending Machine Cost? Typical Price Range (2025) Prices vary based on: Vending Expert offers high-performing, tested units tailored for both indoor and outdoor environments. View our latest machines at How to Find the Best Locations The ideal vending location is: Top-performing location types: Pro tip: Offer property managers a revenue share. It's an easy way to secure placement and build long-term partnerships. What You Need to Get Started Need guidance? Vending Expert is your one-stop solution at — offering tailored machine packages, consulting, and marketing support. Top Features to Look For in a Machine Investing in high-quality tech now saves you thousands in repairs later. 2025 Trends Shaping the Pizza Vending Business Ride these trends to keep your machines competitive and relevant. Is the Pizza Vending Machine Business Right for You? Are you looking for a semi-passive income stream? Do you want to enter the food business without a kitchen or staff? Do you have access to busy locations or real estate contacts? Are you ready to start earning in the next 30–60 days? If you answered yes to these, then this is one of the best business models you'll find in 2025. Final Thoughts The pizza vending machine business is no longer a novelty — it's a serious income-generating model changing the way the world eats. With low barriers to entry, fast ROI, and sky-high demand for hot, convenient meals, this is your chance to step into a profitable venture that runs itself. Ready to get started? Let Vending Expert help you dominate your market with powerful machines, location strategies, and ongoing support. Explore our vending machines at and start building your passive income empire today. Original Source of the original story >> Pizza Vending Machine Business Model: Start Earning Passive Income in 2025
Yahoo
5 hours ago
- Yahoo
Here's Why Exelixis (EXEL) is a Strong Value Stock
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors alike. Achieving those goals is made easier with the Zacks Style Scores, a unique set of guidelines that rates stocks based on popular investing methodologies, namely value, growth, and momentum. The Style Scores can help you narrow down which stocks are better for your portfolio and which ones can beat the market over the long-term. Different than growth or momentum investors, value-focused investors are all about finding good stocks at good prices, and discovering which companies are trading under what their true value is before the broader market catches on. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, and Price/Cash Flow to help pick out the most attractive and discounted stocks. Alameda, CA-based Exelixis, Inc. is an oncology-focused biotechnology company that primarily focuses on the discovery, development and commercialization of new drugs for the treatment of difficult-to-treat cancers. The company is leveraging its investments, expertise and strategic partnerships to target an expanding range of tumor types and indications with its clinically differentiated pipeline of small molecules, antibody-drug conjugates (ADCs) and other biotherapeutics. EXEL is a Zacks Rank #2 (Buy) stock, with a Value Style Score of B and VGM Score of A. Shares are currently trading at a forward P/E of 15.9X for the current fiscal year compared to the Medical - Biomedical and Genetics industry's P/E 19.3X. Additionally, EXEL has a PEG Ratio of 0.8 and a Price/Cash Flow ratio of 21.5X. Value investors should also note EXEL's Price/Sales ratio of 4.9X. A company's earnings performance is important for value investors as well. For fiscal 2025, 10 analysts revised their earnings estimate higher in the last 60 days for EXEL, while the Zacks Consensus Estimate has increased $0.30 to $2.61 per share. EXEL also holds an average earnings surprise of 48.6%. Investors should take the time to consider EXEL for their portfolios due to its solid Zacks Ranks, notable earnings and valuation metrics, and impressive Value and VGM Style Scores. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Exelixis, Inc. (EXEL) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Yahoo
6 hours ago
- Yahoo
Lilly to acquire Verve in $1B bet on gene editing for heart disease
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Eli Lilly agreed to buy Verve Therapeutics for $1 billion, betting on the promise of one-and-done gene therapies to treat cardiovascular disease. The deal announced Tuesday offers Verve stockholders $10.50 a share, plus a contingent value right worth another $3 a share. The non-tradeable CVR would pay out if the company's experimental VERVE-102 treatment advances enough to dose a patient in a Phase 3 trial within 10 years of the transaction's closing. Verve CEO Sekar Kathiresan and other top stockholders have already agreed to tender shares that represent about 17.8% of Verve's outstanding stock and the gene editing company's board recommends that all investors agree to the tender offer, Lilly said. A second-step merger will follow if needed. The companies expect to complete the transaction in the third quarter. For Lilly, the acquisition offers greater control of a pipeline it's already invested in. The company inked a deal with Verve in 2023 to develop a product now known as VERVE-301 that's still in preclinical research. Later that year, Lilly bought other Verve opt-in rights from Beam Therapeutics that include the program for VERVE-102. 'The deal makes sense for Verve shareholders and makes sense given the exposure Lilly has to Verve's entire disclosed pipeline,' William Blair analyst Myles Minter wrote in a note to clients. Lilly is also stepping in at a time when Verve shares are undervalued, Minter said. Verve went public in 2021 with one of the largest initial offerings of the year in the biotech industry, raising almost $270 million by selling shares at $19 each. As an investment boom continued that year amid high hopes for gene therapies, Verve's shares soared above $70. But the company's lead product, VERVE-101, encountered safety concerns and Verve decided to scrap it in favor of a successor, VERVE-102, that used a different lipid nanoparticle for delivery of the treatment. That product has shown early promise. Even so, Verve shares closed at $6.27 yesterday, hurt by a general slump in investment in cell and gene therapy companies. 'Eli Lilly is getting a bargain here,' Minter wrote. Still, the 67% premium to the current share price is 'a win for Verve shareholders and the gene editing space more broadly, which has been under significant macro pressure in a difficult funding environment.' The CVR is likely to pay out, Minter said. The timeframe of 10 years shouldn't be an issue; dosing in a Phase 3 trial is more dependent on continued demonstration of safety in earlier-stage research, he wrote. The larger question for Lilly is whether patients and doctors will embrace genetic medicines for cardiovascular disease, when more traditional treatment options are readily available. Other companies have struggled in that situation. Verve counters that many patients drop off standard medications, putting themselves in danger of complications like a heart attack. The company's lead product is administered as an infusion, which also sets it apart from the complicated administration process that underlies high-profile gene editing treatments such as Vertex's Casgevy. Verve's medicine 'could shift the treatment paradigm for cardiovascular disease from chronic care to one-and-done treatment,' Ruth Gimeno, Lilly's group vice president for diabetes and metabolic research and development, said in the company's press release. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
